Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Colorcon
Mallinckrodt
Boehringer Ingelheim
Harvard Business School

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Litigation Details for Coherus Biosciences, Inc. v. Amgen Inc. (D. Del. 2019)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Coherus Biosciences, Inc. v. Amgen Inc. (D. Del. 2019)

Docket   Start Trial Date Filed 2019-01-24
Court District Court, D. Delaware Date Terminated 2019-11-26
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand Plaintiff Referred To
Parties AMGEN INC.; COHERUS BIOSCIENCES, INC.
Patents 10,155,039; 10,159,732; 10,159,733; 10,207,000
Attorneys Brian P. Egan; Jack B. Blumenfeld; Joseph E. Lasher; Robert M. Oakes; William Chad Shear
Firms Fish & Richardson P.C.; Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Biologic Drugs cited in Coherus Biosciences, Inc. v. Amgen Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Coherus Biosciences, Inc. v. Amgen Inc. (D. Del. 2019)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 Complaint United States Patent Nos. 10,155,039 (“the ’039 patent”), 10,159,732 (“the ’732 patent”), and 10,159,…and continues to infringe the ’039 patent, ’732 patent, and ’733 patent; B) A judgment permanently…further infringement of the ’039 patent, ’732 patent, and ’733 patent; C) A judgment awarding…Amgen’s infringement of the ’039 patent, ’732 patent, and ’733 patent was deliberate and willful; …10,159,733 (“the ’733 patent”) under the Patent Laws of the United States, 35 U.S.C. § 1 et seq. External link to document
0000-00-00 18 Answer to Counterclaim The Patents-In-Suit 112. U.S. Patent No. 10,155,039 (“the ’039 patent”), titled “Stable…Non-Infringement and Invalidity of U.S. Patent No. 10,155,039 117. Amgen restates and incorporates… U.S. Patent No. 9,114,166 (the “’166 patent”), U.S. Patent No. 8,916,157 (the “’157 patent”), and…Asserted Patents, for example, U.S. Patent No. 9,272,041 (the “’041 patent”) and U.S. Patent No. …and ’714 patents are more relevant than the ’166 patent, the ’157 patent, and the ’583 patent to the External link to document
0000-00-00 3 Patent/Trademark Report to Commissioner Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 10,155,039; US 10,159,732; US… 26 November 2019 1:19-cv-00139 830 Patent Plaintiff District Court, D. External link to document
0000-00-00 53 Order Amgen") for infringement of U .S. Patent Nos. 10,155 ,039, 10, 159,732, and 10,159,733 on January…WHEREAS, Coherus amended its complaint to add U.S. Patent No. 10,207,000 on March 5, 2019 (D.I. 7); …non-infringement, invalidity, and unenforceability of the patents-in-suit on April 18, 2019 (D.I. 10); IT… 26 November 2019 1:19-cv-00139 830 Patent Plaintiff District Court, D. External link to document
0000-00-00 54 Patent/Trademark Report to Commissioner of Patents Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 10,155,039; US 10,159,732; US… 26 November 2019 1:19-cv-00139 830 Patent Plaintiff District Court, D. External link to document
0000-00-00 7 Amended Complaint United States Patent Nos. 10,155,039 (“the ’039 patent”), 10,159,732 (“the ’732 patent”), 10,159,733 …continues to infringe the ’039 patent, ’732 patent, ’733 patent, and ’000 patent; B) A judgment… infringement of the ’039 patent, ’732 patent, ’733 patent, and ’000 patent; C) A judgment… infringement of the ’039 patent, ’732 patent, ’733 patent, and ’000 patent was deliberate and willful…10,159,733 (“the ’733 patent”), and 10,207,000 (“the ’000 patent”) under the Patent Laws of the United States, External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
McKinsey
Johnson and Johnson
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.